# US 2012/0231090 A1 · Molecular biomarker set for early detection of ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231090 A1
- Document ID: US20120231090A1
- Status: Published application
- Kind: A1
- Application number: 13/415,004
- Filed: 2012-03-08
- Published: 2012-09-13
- Earliest claimed: 2011-03-08
- Assignees: King Abdullah University of Science and Technology
- Inventors: Vladimir Bajic; Mandeep Kaur
- Web page: https://patentgrep.com/patent/US20120231090A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- G01N 33/57545: of the ovaries
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2800/50: Determining the risk of developing a disease
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.

## Claims

### Claim 1

A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of assaying for expression of TFAP2A in the individual.

### Claim 2

A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control.

### Claim 3

A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of detecting expression of TFAP2A in an individual, wherein expression of TFAP2A indicates the presence of ovarian cancer or the risk of developing ovarian cancer in the individual.

### Claim 4

A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the steps:
a) comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control, and
b) comparing the expression level of CA125 or E2F5 from the individual with the expression level of CA125 or E2F5 from a control.

### Claim 5

A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the step of comparing the expression level of TFAP2A, CA125 and E2F5 from the individual and the expression level of TFAP2A, CA125 and E2F5 from a control.

### Claim 6 (depends on 5)

The method of claim 5, wherein the protein level of TFAP2A, CA125, and/or E2F5 from the individual is determined.

### Claim 7 (depends on 6)

The method of claim 6, wherein the protein level of TFAP2A, CA125, and/or E2F5 is determined from the blood of the individual.

### Claim 8 (depends on 6)

The method of claim 6, wherein the protein level of TFAP2A, CA125, and/or E2F5 is determined with an antibody.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antibody is a monoclonal antibody.

### Claim 10 (depends on 5)

The method of claim 5, wherein the mRNA level of TFAP2A, CA125, and/or E2F5 from the individual is determined.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mRNA level of TFAP2A is determined from ovarian tissue or blood from the individual.

### Claim 12 (depends on 10)

The method of claim 10, wherein the mRNA level is determined by microarray, Northern, or RT-PCR.

### Claim 13 (depends on 5)

The method of claim 5, wherein the control is tissue or blood from one or more normal individuals or is from tissue or blood from the individual.

### Claim 14 (depends on 5)

The method of claim 5, wherein the method detects the stage of ovarian cancer in the individual.

### Claim 15 (depends on 5)

The method of claim 5, wherein the method further comprises a step of detecting the stage of ovarian cancer in the individual.

### Claim 16 (depends on 14)

The method of claim 14, wherein the stage is stage IA, IC, IIIC, or a combination thereof.

### Claim 17 (depends on 5)

The method of claim 5, further comprising the step of performing an additional ovarian cancer detection method.

### Claim 18 (depends on 17)

The method of claim 17, wherein the additional ovarian cancer detection method is selected from the group consisting of palpitation, ultrasound, magnetic resonance imaging, X-ray, CT scan, blood testing, and biopsy.

### Claim 19 (depends on 5)

The method of claim 5, further comprising the step of administering treatment for ovarian cancer.

### Claim 20 (depends on 5)

The method of claim 5, further comprising the step of obtaining a sample from the individual.

### Claim 21 (depends on 5)

The method of claim 5, further comprising the step of isolating TFAP2A protein and/or mRNA from the sample.

### Claim 22 (depends on 5)

The method of claim 5, further comprising the steps of obtaining a sample from the individual and isolating TFAP2A protein and/or mRNA from the sample.

### Claim 23 (depends on 5)

The method of claim 5, further comprising the step of comparing the level of CA125, E2F5, or both from a sample from the individual with the expression level of CA125, E2F5, or both, respectively, from a control.

### Claim 24

A kit comprising one or more detection reagents for TFAP2A and optionally one or more detection reagents for one or both of CA125 and E2F5, said reagents housed in a suitable container.

### Claim 25 (depends on 24)

The kit of claim 24, wherein the reagent is selected from the group consisting of antibody, microarray, oligonucleotide, polymerase, deoxyribonucleotides, buffer, or a combination thereof.

### Claim 26 (depends on 24)

The kit of claim 24, further comprising an apparatus for drawing blood or taking a biopsy from an individual.

### Claim 27

A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the steps of
a) obtaining a sample from the individual,
b) determining the expression level of TFAP2A from the sample, and
c) comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control.

### Claim 28

A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, comprising the steps of
a) obtaining a sample from the individual,
b) determining the expression level of TFAP2A from the sample,
c) determining the expression level of CA125 and/or E2F5 from the sample,
d) comparing the expression level of TFAP2A from the individual with the expression level of TFAP2A from a control, and
e) comparing the expression level of CA125 and/or E2F5 from the individual with the expression level of CA125 and/or E2F5 from a control.
